Dose modifications for Portrazza1

Dose modifications chart
Zoom In
Zoom Out
  • In SQUIRE, 1.5% of patients in the Portrazza plus gemcitabine and cisplatin arm experienced IRRs of any severity, with 0.4% reported as having grade 3 IRRs1
  • Hypomagnesemia1
  • Withhold Portrazza for grade 3 or 4 electrolyte abnormalities
  • Once hypomagnesemia and related electrolyte abnormalities have improved to grade ≤2, may resume Portrazza for subsequent cycles
  • Replete electrolytes as medically appropriate

IRR=infusion-related reaction.

Reference: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.